Phase 2 Trial of PRA023 in SSc-ILD Patients Planned for Next Year

Phase 2 Trial of PRA023 in SSc-ILD Patients Planned for Next Year

314187

Phase 2 Trial of PRA023 in SSc-ILD Patients Planned for Next Year

Prometheus Biosciences is planning a clinical trial of its investigational anti-inflammatory and antifibrotic medication PRA023 in people with systemic scleroderma-associated interstitial lung disease (SSc-ILD), a form of scleroderma characterized by inflammation and scarring (fibrosis) in the lungs. The Phase 2 study, called ATHENA-SSc-ILD, is planned to launch early next year. The U.S. Food and Drug Administration (FDA) has already given clearance for the trial, which aims to enroll about 100 patients who will be randomly…

You must be logged in to read/download the full post.